Skip to Content
U.S. National Institutes of Health
Last Updated: 06/26/14

Spotlight On…

The Investigational Drug Steering Committee (IDSC)
The Investigational Drug Steering Committee (IDSC) was established following recommendations by the Clinical Trials Working Group (CTWG). The IDSC was created to collaborate with NCI in the design and prioritization of early phase drug development trials with agents for which CTEP holds an IND. IDSC members include the Principal Investigators of CTEPs Experimental Therapeutics Clinical Trail Network (ETCTN), representatives from the each of the Cooperative Groups that comprise the National Clinical Trial Network (NCTN), a patient advocate, and Subject Matter Experts in drug development, radiation oncology, clinical pharmacology, clinical immunology, clinical trial design, omics, biostatistics and imaging. More…

The NCI Experimental Therapeutics Program (NExT)
DCTD and the Center for Cancer Research (CCR) are working in close collaboration to reinvigorate cancer drug development at NCI. Through a joint early therapeutics development program, extramural and intramural teams have prioritized a pipeline of NCI-driven targeted therapeutics for development. This program, called the NCI Experimental Therapeutics (NExT) program, combines the strengths of DCTDs extensive expertise in anticancer drug development with CCRs dynamic in-house research and its location within state-of-the-art facilities at the NIH Clinical Center. More…

Operational Efficiency Working Group (OEWG)
CTEP is working with investigators to implement the recommendations of the OEWG presented by Dr. James Doroshow, Director of the NCI Division of Cancer Treatment and Diagnosis, to the NCI Clinical Trials and Translational Research Advisory Committee. The goal of the OEWG recommendations is to shorten the timeline necessary for trial activation. More…